EVENT BROCHURE

CGT MANUFACTURING DACH 2027

ENHANCING SPEED & QUALITY IN CELL & GENE THERAPY MANUFACTURING FOR THE DACH REGION

17–18 February 2027

OFFICIAL EVENT BROCHURE

https://infohub.imapac.com/cgt-manufacturing-dach-2027

Table of Contents

EVENT HIGHLIGHTS

250+ ATTENDEES

100+ COMPANIES

30+ EXPERT SPEAKERS

DATE & VENUE

17-18 February 2027

Munich
Germany

CO-LOCATED EVENTS

OPX OLIGOS & PEPTIDES CDMFEX 2027 DACH EDITION

BIO LOGICS MANUFACTURING DACH 2027

About the Event

Bringing together 250+ CGT manufacturing, process development, technology, regulatory and operations leaders across the DACH region to tackle the challenges of scaling, automation, GMP manufacturing, process optimisation and commercialisation.

WHO / WHAT / WHY

WHO

250+ cell & gene therapy manufacturing leaders, operators, regulators and technology partners from across the DACH ecosystem.

WHAT

DACH's focused forum on the practical execution of cell and gene therapy manufacturing — from process transfer and automation to GMP scale-up, biosafety and supply continuity.

WHY

Tackle the critical challenges holding CGT manufacturing back: capacity, regulatory complexity, cost, technology transition and commercial scale-up.

WHAT TO EXPECT

250+
Senior Attendees

30+
Expert Speakers

100+
Companies Represented

About the Event

WHAT IS NEW IN 2027?

CGT MANUFACTURING DACH 2027

This year introduces the DACH Bioprocessing Excellence Awards, recognising manufacturing innovation, operational excellence, and leadership across cell & gene therapy, biologics, and oligos & peptides.

The programme brings cell & gene therapy, biologics, and oligos & peptides together in one agenda, reflecting the shift toward multi-platform and hybrid manufacturing models.

There is a stronger emphasis on late-stage CMC, tech transfer, GMP readiness, and cost-of-goods, aligning discussions with real-world commercialisation challenges.

New sessions highlight digital and automated manufacturing, including digital twins, PAT, real-time release testing, and closed-system operations.

The agenda places greater focus on patient-centric and decentralized CGT models, covering autologous manufacturing, point-of-care production, and chain of identity.

Discussions are tailored to DACH-specific operational and sustainability priorities, including facility design, supplier risk, energy efficiency, and regional regulatory expectations.

Agenda at a Glance

DAY 1 | 17 FEBRUARY 2027	DAY 2 | 18 FEBRUARY 2027
CGT MANUFACTURING DACH 2027	CGT MANUFACTURING DACH 2027
Commercialising Cell & Gene Therapies: Scaling for Global Success	Bridging the CGT Scale-Up & Tech Transfer Gap
NETWORKING BREAK	
Scaling Cell Therapy Manufacturing	Quality, GMP & Regulatory Control in CGT Manufacturing
LUNCH	
Overcoming Bottlenecks in Viral Vector Manufacturing	Novel Biosafety and Contamination
NETWORKING BREAK	
Industry Roundtables: The Future of CGT Manufacturing	Supply Chain, Logistics & Commercial Readiness
END OF CONFERENCE DAY 1	END OF CONFERENCE

CGT MANUFACTURING DACH 2027

Day 1

17 February 2027

08:00 **Registration & Coffee**

08:50

Chairman's Welcome Address

Nicoletta Loggia
Chief Technology Officer, Orchard Therapeutics, Switzerland

Commercialising Cell & Gene Therapies: Scaling for Global Success

09:00

Scaling Viral Vector & Cell Therapy Manufacturing for Commercial Readiness

- Overcoming scale-up bottlenecks in viral vector production (lentiviral, AAV)
- Managing process consistency from development to GMP manufacturing
- Manufacturing considerations across T-cell, NK-cell, and CD34 stem cell therapies
- Bridging the gap between small-scale development and industrial production

Nicoletta Loggia
Chief Technology Officer, Orchard Therapeutics, Switzerland

09:30 **Reserved for Solution Provider**

10:00

PANEL DISCUSSION

Building Sustainable CGT Business Models: From Clinical to Commercial

- Impact of funding constraints and milestone-driven investment
- Cost of goods and manufacturing scalability challenges
- Ensuring long-term operational and commercial sustainability
- Aligning manufacturing strategy with market access and growth

PANELISTS

Chris Baldwin
Vice President, Manufacturing and Supply, Resolution Therapeutics, UK

Parag Kumthekar
Lead Gene Therapy Downstream Team, UCB, Belgium

10:30 **Networking Break**

Day 1

17 February 2027

Scaling Cell Therapy Manufacturing

11:10

Scaling Non-Viral T-Cell Engineering: Bridging Process Development and GMP Manufacturing (TBC)

- Translation from small-scale development to clinical manufacturing
- Large-scale CRISPR knock-in and knock-out
- Maintaining editing efficiency, viability and cell quality
- Reproducibility across different donors and starting materials

Gulbengu Kuzgun Yuksel
Network Head of Quality Cell & Gene Therapy, Roche, Switzerland

11:40

Reserved for Solution Provider

12:10

Scaling CAR-T Manufacturing: From Clinical Success to Commercial Delivery

- Overcoming manufacturing bottlenecks in autologous CAR-T production
- Improving vein-to-vein timelines through process optimisation
- Increasing manufacturing capacity while maintaining product quality
- Preparing CAR-T platforms for sustainable commercial supply

13:00

Lunch

Overcoming Bottlenecks in Viral Vector Manufacturing

14:00

Scaling Viral Vector Manufacturing: From Development to GMP Production

- Addressing scale-up challenges in lentiviral and AAV production
- Managing process variability between R&D and GMP environments
- Bridging development processes with commercial manufacturing requirements
- Reducing risk during tech transfer and engineering runs

Parag Kumthekar
Lead Gene Therapy Downstream Team, UCB, Belgium

Day 1

17 February 2027

14:30

Reserved for Solution Provider

15:00

Improving Yield, Consistency & Cost Efficiency in Viral Vector Production

- Enhancing process robustness and reproducibility at scale
- Tackling low yields in complex vector manufacturing processes
- Optimising upstream and downstream performance for efficiency gains
- Balancing cost pressures with clinical and commercial demand

15:30

Networking Break

16:00

ROUNDTABLE DISCUSSION

1. Can CGTs Become Truly Commercially Viable?
2. Exploring Advances in Viral Vector Manufacturing (TBC)
   Parag Kumthekar — Lead Gene Therapy Downstream Team, UCB, Belgium
3. What Does "GMP" Really Mean for Early-Phase ATMPs?
4. Industrialising CGT: Automation vs Practical Reality
5. Building Scalable CGT Manufacturing Models for the Next Decade (TBC)
   Gulbengu Kuzgun Yuksel — Network Head of Quality Cell & Gene Therapy, Roche, Switzerland

17:00

Cocktail Reception

17:15

END OF CONFERENCE DAY 1

Day 2

18 February 2027

08:00 **Registration & Coffee**

08:50 **Chairman's Welcome Address**

Bridging the CGT Scale-Up & Tech Transfer Gap

09:00

Why CGT Tech Transfer Fails — From R&D to GMP Reality

- Fundamental mismatch between lab-scale and GMP manufacturing environments
- Limited opportunity for full-scale optimisation due to cost and material constraints
- Environmental and operational differences between development and production sites
- Hidden failure points emerging only during GMP execution

Marion Hitchcock
Managing Director Gene & Cell Therapies Incubator, Bayer, Germany

09:30 **Reserved for Solution Provider**

10:00

Manufacturing Strategies Across CD34 Stem Cell, T-Cell & NK-Cell Therapies

- Platform-specific manufacturing challenges across CD34 stem cells, T- Cells, and NK-Cells
- Optimising process development and scale-up for different cell therapy modalities
- Technology transfer considerations from clinical to commercial manufacturing
- Ensuring process robustness, comparability, and manufacturing consistency across diverse cell therapy platforms

10:30 **Networking Break**

Quality, GMP & Regulatory Control in CGT Manufacturing

Day 2

18 February 2027

11:10

PANEL DISCUSSION

The Future of CAR-T Manufacturing: In Vivo vs Ex Vivo Approaches Towards 2030

- In vivo vs ex vivo: how quickly will the manufacturing model evolve?
- 2030, 2035 or 2040: when could in vivo CAR-T become commercially viable?
- Cost & scalability: Can in vivo approaches reduce cost per patient and improve accessibility?
- Safety: managing the risks of in vivo vector delivery and long-term effects.

PANELISTS

Bart Van Waeyenberge
EMEA Head of CAR T Operations, Johnson & Johnson, Belgium

11:40

Reserved for Solution Provider

12:10

Navigating GMP & Regulatory Complexity in Cell & Gene Therapy

- Non-harmonised expectations across EMA vs FDA and global regulators
- Evolving GMP expectations for early-phase vs commercial CGT manufacturing
- Assay validation, comparability, and starting material scrutiny challenges
- Regulatory uncertainty during tech transfer from academic to GMP environments

13:00

Lunch

Novel Biosafety and Contamination

14:00

How can CGT manufacturers strengthen biosafety controls without slowing development?

- Managing contamination risk across donor material, starting materials, viral vectors, and open processing steps
- Balancing rapid methods, assay sensitivity, and GMP/regulatory expectations
- Strengthening investigation and decision-making pathways when atypical results arise
- Building scalable contamination-control strategies as programmes move from early clinical to commercial supply

Day 2

18 February 2027

14:30 — **Reserved for Solution Provider**

15:00

Building a Phase-Appropriate Biosafety Strategy for Cell and Gene Therapy Manufacturing

- Defining biosafety-testing needs according to modality, process risk, and clinical stage
- Integrating cell-bank, raw-material, in-process, and product testing into one coherent control strategy
- Reducing turnaround-time risk while maintaining confidence in product safety and quality
- Preparing biosafety methods and controls for tech transfer, scale-up, and commercial readiness

15:30 — **Networking Break**

Supply Chain, Logistics & Commercial Readiness

16:00

Managing Critical Material Shortages in CGT Manufacturing

- Viral vectors, plasmids and raw material bottlenecks
- Long lead times and limited supplier base
- Impact of material constraints on GMP production timelines
- Practical mitigation strategies used by manufacturers today

16:30

What Breaks When CGTs Move from Clinical to Commercial Supply?

- Tech transfer failures impacting supply continuity
- Scaling manufacturing networks under GMP constraints
- Misalignment between development timelines and manufacturing reality
- Operational challenges in sustaining commercial supply

17:00 — **Closing Remarks**

17:15 — **END OF CONFERENCE DAY 1**

MEET THE SPEAKERS

CGT MANUFACTURING DACH 2027

CHAIRMAN

Nicoletta Loggia

Chief Technology Officer
Orchard Therapeutics
SWITZERLAND

Marion Hitchcock

Managing Director Gene & Cell Therapies Incubator
Bayer
GERMANY

Chris Baldwin

Vice President, Manufacturing and Supply
Resolution Therapeutics
UK

Gulbengu Kuzgun Yuksel

Network Head of Quality Cell & Gene Therapy
Roche
SWITZERLAND

Bart Van Waeyenberge

EMEA Head of CAR T Operations
Johnson & Johnson
BELGIUM

Parag Kumthekar

Lead Gene Therapy Downstream Team
UCB
BELGIUM

OPX OLIGOS & PEPTIDES CONFEX 2027 DACH EDITION

Volker Derdau

Head Center of Excellence Isotope Chemistry, Senior Distinguished Scientist

Sanofi

GERMANY

Dr. Ulrich Rümenapp

Senior Biotech Program Lead

Bayer

GERMANY

Hagen Cramer

Chief Technology Officer

QurAlis

USA

Dr. Cecile Brocard

Head of Downstream Development

Boehringer Ingelheim

AUSTRIA

Karoline Bechtold-Peters

Director Science & Technology - Scientific Office/Drug Product Development/Global Biologics & CGT

Novartis

SWITZERLAND

Carl Reens

Principal Scientist, Global Chemical Development

AstraZeneca

UK

Gnana Oli Rajaraman

Associate Director Bioanalytics

AiCuris

GERMANY

BIOLOGICS MANUFACTURING DACH 2027

Baerbel Grossmann
Associate Director Global Regulatory Affairs CMC Biologics
Sanofi
GERMANY

Bettina Knapp
Head of Digital Operations Drug Substance
Boehringer Ingelheim Pharma
GERMANY

Alessio Epifanio
Director, Environmental Health, Safety & Sustainability
J&J Innovative Medicine
ITALY

Melanie Dannemeyer
Associate Director Tech Transfer
AstraZeneca
SWEDEN

Frank Seibel
Quality Site Head, Vice President
Roche
GERMANY

Maximilian Abress
Senior Director Global Supply Chain
BioNTech
GERMANY

Karin Keppeler
Associate Director E2E Supply Chain
BioNTech
GERMANY

Roberto Corazza
Operational Excellence, Digital and Strategy Director
J&J Innovative Medicine
ITALY

Sponsors & Media Partner

GOLD

clean cells
SOLUTION FOR BIOLOGICS

BioReliance®
Contract Testing Services

Our Past Partners

Our Past Partners (cont.)

Our Past Partners (cont.)



DACH Series Past Partners



Expected Audience Snapshot

90%
BIOPHARMA & BIG PHARMA

10%
SERVICE & SOLUTION PROVIDERS

BY PROFILE

Large Pharma & Biopharma Manufacturers	51%
Emerging Biotech	39%
Academia & Research Institutes	8%
Regulatory / Public Health Bodies	2%
CDMOs	1%

BY JOB TITLE

Executive Leadership (C-Suite / Founders / MDs)	27%
Process Development & MSAT	14%
R&D / Scientific	12%
Manufacturing & Operations	8%
Quality & Compliance	7%
Supply Chain & External Manufacturing	4%
Business Development & Commercial	3%
Regulatory Affairs	3%
Medical & Clinical Affairs	3%
Engineering, Automation & Digitalisation	1%
Other / General Management	20%

DECISION MAKERS

Decision Makers	95%
Others	5%

BY GEOGRAPHY



Targeted Attendees List

Companies and senior roles represented across the selected event(s)

JOB TITLE	COMPANY	COUNTRY
Job Title	Company	Country
Associate Director Gene Therapy	Boehringer Ingelheim	Germany
Cell & Gene Therapy Value Chain Delivery Lead	Roche	Switzerland
Regulatory CMC Senior Director - Biologics & Gene Therapies at Ultragenyx	Ultragenyx	Switzerland
Manager Cell & Gene Therapies/ Project Manager - Cell & Gene Therapies Business Operations	F. Hoffmann-La Roche AG	Switzerland
Associate Director Analytical Development	T-knife Therapeutics	Switzerland
Co-founder and CEO	CDR-Life	Switzerland
CTO	Orchard TX	Switzerland
Associate Director Analytical Development CMC	Gyroscope Therapeutics	United Kingdom
CEO and Co-founder	T3 Pharmaceuticals	Switzerland
MSAT Scientist, Cell and Gene Therapy	Novartis	Switzerland
Analytical Development Scientist | Gene Therapy	UCB	Belgium
Principal Scientist in Gene Therapy Research	CSL Behring	Switzerland
Head of Pharmaceutical Development	SmartImmune	France
VP Process Research	Autolus Ltd.	United Kingdom
Global Sr. Director Audit and Inspection Management	Pfizer	Spain
Senior Scientist	Institute for Transfusion Medicine and Gene Therapy	Germany
Product Operations Lead - Cell Therapy	Takeda	Switzerland
Associate Director Gene Therapy	Boehringer Ingelheim	Germany
Cell & Gene Therapy Value Chain Delivery Lead	Roche	Switzerland
Regulatory CMC Senior Director - Biologics & Gene Therapies at Ultragenyx	Ultragenyx	Switzerland

Targeted Attendees List (cont.)

JOB TITLE	COMPANY	COUNTRY
Manager Cell & Gene Therapies/ Project Manager - Cell & Gene Therapies Business Operations	F. Hoffmann-La Roche AG	Switzerland
Associate Director Analytical Development	T-knife Therapeutics	Switzerland
Co-founder and CEO	CDR-Life	Switzerland
CTO	Orchard TX	Switzerland
Associate Director Analytical Development CMC	Gyroscope Therapeutics	United Kingdom
CEO and Co-founder	T3 Pharmaceuticals	Switzerland
MSAT Scientist, Cell and Gene Therapy	Novartis	Switzerland
Analytical Development Scientist | Gene Therapy	UCB	Belgium
Principal Scientist in Gene Therapy Research	CSL Behring	Switzerland
Head of Pharmaceutical Development	SmartImmune	France
VP Process Research	Autolus Ltd.	United Kingdom
Global Sr. Director Audit and Inspection Management	Pfizer	Spain
Senior Scientist	Institute for Transfusion Medicine and Gene Therapy	Germany
Product Operations Lead - Cell Therapy	Takeda	Switzerland

VIEW THE FULL ATTENDEE LIST →

Sponsorship Opportunities

Sponsorship Packages

DIAMOND

PACKAGE INCLUDES

- Full-day workshop for 30 pax: room, lunch, 2 refreshment breaks, coffee / tea
- Keynote solo presentation: 20 min + 5 min Q&A
- 25-minute end-user client case study
- 12 sqm exhibition space (4×3m booth + banner)
- 1 speaker pass; 7 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

PLATINUM

PACKAGE INCLUDES

- Half-day workshop for 30 pax: room, 1 refreshment break, coffee / tea
- Prime-billing solo presentation: 20 min + 5 min Q&A
- 25-minute end-user client case study
- 12 sqm exhibition space (4×3m booth + banner)
- 1 speaker pass; 7 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

GOLD

PACKAGE INCLUDES

- Prime-billing solo presentation: 20 min + 5 min Q&A
- 9 sqm exhibition space (3×3m booth + banner)
- 1 speaker pass; 5 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

SILVER (ENHANCED)

PACKAGE INCLUDES

- Solo presentation: 20 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth + banner)
- 1 speaker pass; 3 guest passes; 2 exhibitor passes
- 5 onsite 1:1 meetings
- Lead retrieval

SILVER

PACKAGE INCLUDES

- Solo presentation: 10 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth + tabletop display)
- 1 speaker pass; 2 guest passes; 2 exhibitor passes
- 5 onsite 1:1 meetings
- Lead retrieval

BRONZE

PACKAGE INCLUDES

- Solo presentation: 10 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth)
- 1 speaker pass; 2 guest passes
- Lead retrieval

EXHIBITION + 10 MEETINGS

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- 10 onsite 1:1 meetings
- Lead retrieval

EXHIBITION + 5 MEETINGS

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- 5 onsite 1:1 meetings
- Lead retrieval

EXHIBITION

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- Lead retrieval

Sponsorship Opportunities

CGT MANUFACTURING DACH 2027

Who Should Sponsor?

- Cell Isolation & Processing Systems
- Cryopreservation, Storage & Cold Chain Logistics
- Viral Vector Manufacturing
- Analytical Testing, Quality Control & Release Assays
- Gene Editing & Cell Engineering Technologies
- Sterility Testing & Microbiology Solutions
- Cell Culture Media, Reagents & Consumables
- CDMOs & Contract Manufacturing Services
- Cell Expansion & Bioreactor Technologies
- Raw Materials, Plasmids & Critical Components
- Single-Use Bioprocessing Systems
- Engineering, Cleanroom & Facility Design
- Process Monitoring, Automation & Digital Manufacturing
- Regulatory, Validation & Quality Services
- Cell Harvesting, Washing & Formulation Technologies
- Chain of Identity / Chain of Custody Solutions
- Aseptic Fill-Finish Solutions
- Clinical Supply Chain & Logistics Providers

Why Sponsor

SPONSORSHIP BENEFITS

- Thought Leadership Speaking
- Panel Participation
- Solution Showcases
- Engagement and Visibility Opportunities
- Branding and Digital Visibility
- Exclusive Networking

TESTIMONIALS

The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.

Dr Heiner Apeler
VP Head of Biologics Development
Bayer
GERMANY

Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey's development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal.

John Bridgeman
CSO
Immunokey
UK

Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I'm excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!

Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS
SWITZERLAND

TESTIMONIALS (cont.)

Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators

Dr Andrew Kelly
Director, Manufacturing Technology
BMS
IRELAND

A fantastic deep dive into the DACH region's CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together.

Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW
SWITZERLAND

Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees.

Brian O'Connor
VP Global Quality
Orchard Therapeutics
UK

Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!

Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda
SPAIN

TESTIMONIALS (cont.)

I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants.

Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche
SWITZERLAND

I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.

Terry Gray
Field Marketing Manager
Merck

Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event

Warren Roche
Senior Statistical Expert
Sanofi
IRELAND

Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event. I hope we have opportunity to connect again in the future.

Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease
IRELAND

Well done on a very informative and successful event.

Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT
IRELAND

MARK YOUR CALENDAR

Save the Date

17–18 FEB 2027 Munich

CGT Manufacturing DACH 2027

ALL IMAPAC EVENTS

Explore Our Full Event Calendar

Discover upcoming IMAPAC biopharmaceutical conferences, summits, and exhibitions across Europe and worldwide. →

OR ADD THIS EVENT TO YOUR CALENDAR

Google Calendar
One-click add to Gmail →

Outlook Calendar
Add to Microsoft Outlook →

Scan to Register

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our global audience spanning the sub-sectors and regions shaping the biopharmaceutical industry.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

Learn More →

HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE
imapac.com

EMAIL
info@imapac.com

IMAPAC PTE LTD
36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD
77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN
@imapac

X
@imapac

FACEBOOK
ImapacPteLtd